Omniab, Inc. · NASDAQ:OABI
Omniab — Investor Presentation (January 2023)
38 slides from Omniab's investor presentation, Jan 9, 2023
Slide 1: OmniAb, Inc. January 2023
OmniAb, Inc. Nasdaq: OABI January 2023 Exhibit 99.1
Slide 2: Forward-looking statements
We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected cash runway, business strategy, our exp
Slide 3: One of the largest greenfields in the pharma industry
OmniAb, Inc. ONE OF THE LARGEST GREENFIELDS IN THE PHARMA INDUSTRY >65 partners HAVE ACCESS TO OMNIAB ANTIBODIES >280 Programs and 3 PRODUCT approvals Transgenic animals for fully human and Bispecific antibody Discovery LEADING AND PROVEN TECHNOLOGY INDUSTRY’S ONLY 4-SPECIES PLATFORM $279 Billion To
Slide 4: Mission
Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. Mission
Slide 5: Antibodies and Industry Demand
Type of Drug Clinical Success Rates(1) Small Molecules 7.5% Antibodies 12.1% Sources: Clarivate Analytics Cortellis database. Tables of approved mAbs and antibodies in review available at: https://www.antibodysociety.org/resources/approved-antibodies/ (1) Defined as composite success rate of clinica
Slide 6: Growth of Partner Programs
Growth of Partner Programs Progression and Performance in Programs by Stage of Development 21 as of 2016(1) 282 as of 09/30/22 (1) Estimated at the time of acquisition of OMT, Inc. Substantial progress in all phases, increase in discovery programs expected to feed growth in new clinical programs and
Slide 7: The OmniAb Platform
The OmniAb Platform We leverage our proprietary and differentiated technologies, rather than commoditized industry services that are widely available from CROs or built into big pharma Create Diverse Pools of High-Quality Naturally-Optimized Antibodies Screen Millions of Cells to Find Potential Ther
Slide 8: The OmniAb Technology Offering
The OmniAb Technology Offering Technology offering addresses the most critical challenges of antibody discovery Technologies Create Diverse Antibody Pools Screen Antibody Candidates Identify the Right Antibody Create Diverse Pools of High-Quality Naturally-Optimized Antibodies Screen Millions of Cel
Slide 9: What is Biological Intelligence?
What is Biological Intelligence™? We believe that antibodies generated in vivo are superior to ones from other sources because they are naturally optimized through an iterative process that preferentially selects for antibodies with excellent specificity and developability profiles The ability of th
Slide 10: The OmniAb Platform
The OmniAb Platform We believe generating large and diverse pools of high-quality antibodies increases the likelihood of discovering the antibody with the most desirable therapeutic characteristics Antibodies for Any Target Bispecific Antibody Generation Cow-inspired Antibodies for Difficult Targets
Slide 11: Rodent Platforms
Rodent Platforms Endogenous Ig genes inactivated Expression of full human V gene diversity Streamlined conversion into fully human molecule Geurts et al. Science 2009 Ménoret et al. Eur J Immunol 2010 Osborn et al. J. Immunol. 2013 Well-validated transgene design utilizes rodent constant regions for
Slide 12: OmniChicken Powered By Evolution
OmniChicken Powered By Evolution
Slide 13: OmniTaur: Ultralong CDRH3s Create Novel Binding Domains
OmniTaur: Ultralong CDRH3s Create Novel Binding Domains Unique structural features of ultralong H3 antibodies Novel structure may enable targeting epitopes unreachable by standard antibodies Long H3 domains can be expressed on human VH framework, or alone as ~5kD Picobodies™ CDRH3 Human Cow Stanfiel
Slide 14: Common Light Chain Platforms for Bispecific Antibodies
Common Light Chain Platforms for Bispecific Antibodies standard IgG format to de-risk downstream development† †The Evolution of Bispecifc Antibodies, Nimish Gera https://doi.org/10.1080/14712598.2022.2040987 Monospecific IgG Bispecific IgG Rearranged human VK3-15 light chain combined with diversifyi
Slide 15: Antibody Repertoires
Antibody Repertoires numerous options available to address diverse partner objectives Host V genes Structural and immunological features Benefits for therapeutics discovery and development Full human V gene diversity Choice of light chain isotype Diverse V gene usage and mixed genetic backgrounds Wi
Slide 16: Screening Platforms
Screening Platforms Hybridoma Workflow B-cell Workflow Immunization Isolate B-cells Sequence Bioinformatics enrichment optional Single-cell NGS Expression Validation Screen Fusion Technologies enable screening against difficult targets: GPCRs, ion channels and surface antigens Our powerful single B-
Slide 17: The OmniAb Platform
The OmniAb Platform Data from multi-parameter screening and performance assays used in combination with bioinformatics NGS hit expansion to identify variant antibodies with improved characteristics High-throughput epitope binning and kinetics analysis, and target-specific functional assays Proprieta
Slide 18: Ion Channels and Transporters capabilities
Create Diverse Pools of High-Quality Naturally Optimized Antibodies Screen Millions of Cells to Find Potential Therapeutic Candidates Further Characterize, Select & Optimize the Right Antibody Create Diverse Antibody Pools Screen Antibody Candidates Identify the Right Antibody Ion Channels and Trans
Slide 19: Ion Channels and Transporters
Ion Channels and Transporters Ion channels are key components in a wide variety of biological processes that involve rapid changes in cells Present in all human cells and affect such vital functions as nerve transmission, muscle contraction, cellular secretory processes and fluid movement Have broad
Slide 20: Leveraging Biological Intelligence with Computational Tools
Leveraging Biological Intelligence™ with Computational Tools Biological Intelligence Differentiated sources of antibody sequences In silico developability Sequence liability assessment Comparison to clinical antibodies Structure-based calculations Sequence databases and bioinformatics Customized clo
Slide 21: Antibody Repertoire Source Used
Antibody Repertoire Source Used ACTIVE Partner PROGRAMS DISTRIBUTION OF ANTIBODY REPERTOIRE SOURCES USED TOGETHER FOR BISPECIFICS SOURCE USAGE 24% 62% 14% + + + Multi-species platform provides partners even more diverse repertoires and new target access Common light chain techs being used for flexib
Slide 22: Diverse Drug Formats and Modalities
Diverse Drug Formats and Modalities PRECLINICAL AND CLINICAL OMNIAB MOLECULES Duobody® (IgG4 exchange) ADAPTIR™ scFv-Fc-scFv IgG IgG-scFv Antibody-Drug Conjugate Fab-Heavy chain (Knob-in-hole) Variety in the formats and modalities used by partners is demonstrating the flexibility of our platform MOD
Slide 23: Select OmniAb Partners
Select OmniAb Partners >65 companies currently have access to omniab ANTIBODIES
Slide 24: Key Performance Indicators
Key Performance Indicators Strong annual growth in key performance indicators continues Active Partners:(1) >30% CAGR 2014 through 2021 Active Programs:(2) >25% CAGR 2016 through 2021 Metrics as of 9/30/22 position our business for strong growth Technology and business model are highly scalable Repr
Slide 25: Intellectual Property Advantage
Intellectual Property Advantage Antibody Patent Applications Filed by Partners PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES can CREATE DIVERSE AND DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL >65 patent filings by our partners claiming an OmniAb-derived antibody as primary invention, with e
Slide 26: Business Model
Business Model Our agreements are structured to align economic and scientific interests with our partners License partnerships designed to include: Upfront and collaboration/access fees Milestones Royalties on commercial sales
Slide 27: Illustrative Antibody Deal Structure
Illustrative Antibody Deal Structure Year 0 5 10 15 20 25 Collaboration/ Access Fees: ~$1M - $2M Potential IP Extension Notes: Deal Economics have evolved over time. Unique deal structures may also be used (e.g., equity stakes, risk-sharing, buy-in options, etc.). Not representative of Icagen Ion C
Slide 28: Published Probability of Success and Timelines for Antibodies
Published Probability of Success and Timelines for Antibodies Probability of Success (1) Cumulative from Program Start Cumulative from Clinical Start Time Range in Stage Discovery 100.0% 100.0% ~4 Years Preclinical 51.0% 51.0% Phase 1 69.0% 35.2% 100.0% Phase 2 54.7% 19.2% 54.7% ~5 - 8 Years Phase 3
Slide 29: Building Blocks of Value
Building Blocks of Value Novel Platform Technologies Collaboration Revenue Royalties from Approved Products Milestones from Pre-Clinical and Clinical Progress New Partnership Deals (13 New Licenses signed in 2022)
Slide 30: Proforma Revenue & Operating Expense
Proforma Revenue & Operating Expense
Slide 31: Cash Position Provides Long Operational Runway
Cash Position Provides Long Operational Runway ($ millions) 12/31/22 Cash Balance* ~ $88 Teclistamab/TECVAYLI First Commercial Sale Milestones Received in January 2023 $35 Proforma Cash Position ~ $123 * Includes cash, cash equivalents and marketable securities Business is close to break-even cash f
Slide 32: Share Information
Share Information Ligand shareholders received 0.75842 earnout shares for every Ligand share owned 50% of the earnout shares vest at $12.50, 50% vest at $15.00 Stock must trade for 20 out of 30 consecutive trading days at each respective level for vesting to occur 5-year life Earnout Share Summary A
Slide 33: Management Team
Christel Iffland, PhD SVP, Antibody Technologies Former Associate Director at Merck KGaA / EMD Serono Co-inventor of Avelumab Dana Farber, Albert Einstein College Marie-Cecile Van De Lavoir, PhD, DVM SVP, Technical Operations & Genetics Co-Founder/COO, Crystal Bioscience Origen Therapeutics, Invento
Slide 34: Intelligent expansion of our technology platform
Intelligent expansion of our technology platform is informed by deep relationships with our broad base of partners
Slide 35: Our Key Areas of Focus Going Forward
Our Key Areas of Focus Going Forward We believe we are Well-positioned for future growth while WE MAKE an enduring and significant impact on the industry and global human health Community: Lead with integrity and responsibility Investors: Superior business execution to create value We LEVERAGE A Hig
Slide 36: For more information, please visit www.omniab.com
For more information, please visit www.omniab.com
Slide 37: OmniAb's History
OmniAb’s History Cutting-Edge platform BUILT FROM >15 YEARS of investment and strategic acquisitions Acquired OMT Acquired Crystal Bioscience 2008 2016 2017 2018 2019 2020 OMT, Inc. Founded Acquired Ab Initio (Computationally-Powered Antigen Design) Acquired xCella Acquired Taurus Next-generation an
Slide 38: Approved and Clinical-Stage Partner Pipeline as of 9/30/22
Approved and Clinical-Stage Partner Pipeline as of 9/30/22 Now with Three APPROVED PRODUCTS AND 22 Active CLINICAL-Stage ANTIBODIES Partner Program Source Animal Therapy Area Target Preclinical Phase 1 Phase 2 Phase 3 Registration Approved Zimberelimab OmniRat Oncology PD-1 Sugemalimab OmniRat Oncol